

03.31.2013

INTERIM REPORT

# GROWTH & INNOVATION



## PROFILE

STRATEC DEVELOPS AND MANUFACTURES FULLY AUTOMATED ANALYZER SYSTEMS BASED ON ITS OWN PATENTED TECHNOLOGIES FOR ITS PARTNERS IN THE FIELDS OF CLINICAL DIAGNOSTICS AND BIOTECHNOLOGY. STRATEC'S PARTNERS ARE MOSTLY GLOBAL PLAYERS OPERATING IN THE IN-VITRO DIAGNOSTICS INDUSTRY. THESE COMPANIES MARKET STRATEC'S SYSTEMS UNDER THEIR OWN NAMES, IN GENERAL TOGETHER WITH THEIR OWN REAGENTS, AS SYSTEM SOLUTIONS TO LABORATORIES, BLOOD BANKS, AND RESEARCH INSTITUTES AROUND THE WORLD.

## CONTENTS

- 03 HIGHLIGHTS / KEY GROUP FIGURES AT A GLANCE
- 04 FOREWORD BY THE BOARD OF MANAGEMENT
- 05 INTERIM GROUP MANAGEMENT REPORT
- 09 CONSOLIDATED BALANCE SHEET  
as of March 31, 2013
- 11 CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME  
for the Period from January 1 to March 31, 2013
- 12 CONSOLIDATED CASH FLOW STATEMENT  
for the Period from January 1 to March 31, 2013
- 13 CONSOLIDATED STATEMENT OF CHANGES IN EQUITY  
for the Period from January 1 to March 31, 2013
- 15 NOTES TO THE GROUP INTERIM REPORT  
for the Period from January 1 to March 31, 2013
- 18 ADDITIONAL INFORMATION

## HIGHLIGHTS

Sales of €29.2 million in Q1/2013  
(+14.1%; Q1/2012: €25.6 million\*)

EBIT margin of 15.1% in Q1/2013, up from 12.2% in Q4/2012  
(Q1/2012: 17.0%\*)

Consolidated net income of €3.5 million in Q1/2013  
(+3.1%; Q1/2012: €3.4 million)

Earnings per share of €0.30 in Q1/2013  
(+3.4%; Q1/2012: €0.29)

Updated company forecast planned for release  
by end of H1/2013

## KEY GROUP FIGURES AT A GLANCE

in € thousands	01.01.-03.31.2013	01.01.-03.31.2012	Change
Sales	29,173	25,573 *	+14.1%
EBIT	4,406	4,349	+1.3%
EBIT margin (%)	15.1	17,0 *	-
Consolidated net income	3,544	3,439	+3.1%
Earnings per share (€)	0.30	0.29	+3.4%
No. of employees (absolute)	541	512	+5.7%

in € thousands	03.31.2013	12.31.2012	Change
Shareholders' equity	95,630	91,985	+4.0%
Total assets	128,493	121,838	+5.5%
Equity ratio (%)	74.4	75.5	-

\* 2012 figure adjusted for a one-off item of €3.3 million due to an income-neutral reclassification from unfinished services and prepayments received upon the write-down of a development project. On an unadjusted basis, sales for the first quarter of 2012 amounted to €28.8 million and the corresponding EBIT margin amounted to 15.1%.

## FOREWORD BY THE BOARD OF MANAGEMENT

### Dear Shareholders,

The first quarter of 2013 was positive in many respects, even though we still received only cautiously optimistic signals as to global developments in the IVD industry.

Service part sales, which had still declined disproportionately at the end of the 2012 financial year, have shown a slight recovery since December 2012 and through the first months of 2013. The resultant sales have been far less volatile in their development and have shown a rising tendency. This was one of the main reasons why our EBIT margin began to pick up once again. At 15.1%, our margin still fell notably short of the levels seen in previous years, but nevertheless reflected an equally clear improvement compared with the figure of 12.2% reported for the fourth quarter of 2012. We are continually implementing further measures to enhance our profitability, for example by optimizing the gross profit on newly launched systems, as well as measures aimed at achieving positive earnings contributions from our subsidiaries.

Furthermore, we also brought a major new development and production contract, one that due to its significance and complexity had been in negotiation for a substantial period, to a successful close.

Although competition for highly qualified employees remains tough at the STRATEC Group's main locations, we nevertheless consistently succeed in attracting high-quality staff to the company. Most recently, we have focused in particular on further boosting human resources in our project development and production divisions.

Our proposal to the Annual General Meeting to approve the distribution of a dividend of € 0.50 per share for the 2012 financial year is to be viewed in the light of the increased financing requirements we expect to see due to the growth already foreseeable at our company.

Although it is still premature to speak of any significant turnaround in capacity utilization rates at our customers' network of installed systems or in worldwide test volumes, a recovery is nevertheless already discernible. We are currently preparing our production facilities for further market launches in the coming quarters. Furthermore, based on our customers' forecasts we also expect further growth with analyzer systems already established on the market.

Looking forward, we are confident as to the STRATEC Group's ongoing performance and plan to update our company forecast by the end of the first half of the year.

Birkenfeld, May 2013

The Board of Management of  
STRATEC Biomedical AG



Marcus Wolfinger



Dr. Robert Siegle



Bernd M. Steidle

# INTERIM GROUP MANAGEMENT REPORT

## REPORT ON THE EARNINGS, FINANCIAL AND NET ASSET POSITION

Sales for the first three months of the 2013 financial year increased by 14.1% to € 29.2 million (previous year: € 25.6 million; adjusted for a one-off item of € 3.3 million due to an income-neutral reclassification from unfinished services and prepayments received upon the write-down of a development project). Gross profit (as a percentage of sales) could be increased to € 10.1 million (34.5% of sales), up € 0.5 million compared with the previous year (33.1% of sales). This improvement was driven by a significant increase in the volume of analyzer systems delivered, as well as by efficiency enhancements resulting from measures initiated in 2012 to boost the gross margin.

Gross development expenses and sales-related expenses remained at the previous year's levels, but there was a year-on-year reduction (€ 0.5 million) in the volume of development services capitalized. Administration expenses rose by € 0.4 million to € 2.4 million. This was chiefly due to amendments in the compensation system and the build-up in competence required to support the company's growth course.

The net balance of other operating expenses and income improved by € 0.3 million. The financial result reduced by € 0.2 million. Depreciation and amortization amounted to € 0.9 million, while investments in non-current assets totaled € 0.3 million. EBIT amounted to € 4.4 million (previous year: € 4.3 million), corresponding to an EBIT margin of 15.1% (previous year: 17.0%; net of aforementioned one-off item). The tax result amounted to € 0.8 million. STRATEC can therefore report consolidated net income of € 3.5 million for the period under report (previous year: € 3.4 million). Earnings per share amounted to € 0.30 (previous year: € 0.29).

Given strong demand for analyzer systems and the company's well-stocked development pipeline, inventories rose to € 47.4 million. Receivables and other assets declined by € 2.2 million, a development also reflected in the positive cash flow of € 5.8 million from operating activities. Cash and cash equivalents increased from € 13.2 million to € 18.7 million.

The equity ratio amounts to 74.4%. Non-current financial liabilities could be reduced to € 6.7 million. The increase in trade payables was driven by higher procurement volumes for raw materials and supplies. Within other current liabilities, an amount of € 10.4 million has been reported for prepayments received for development services.

## CHANGES IN THE BUSINESS ENVIRONMENT AND IMPLICATIONS FOR STRATEC

According to the latest forecast issued by the International Monetary Fund (IMF) in April 2013, the global economy has stabilized significantly. The IMF commented that it had been possible in recent months to avert both a collapse in the euro area and a fiasco in US debt policy.

In its forecast, the IMF scaled back the expected level of global economic growth from 3.5% to 3.3%. According to the information in the forecast, the global economy had grown by 3.2% in 2012.

The IMF expects the euro area economy to contract by 0.3% in 2013. This figure has thus been reduced by a further 0.1 percentage points since the previous growth forecast in January 2013. Like Italy and Spain already, France is also set to report negative growth. The IMF has called for a further easing in monetary policy in Europe so as to stimulate private demand and boost the below-average rate of growth compared with other countries around the world. Furthermore, the European banking sector should also be further strengthened.

For 2014, the IMF has forecast a recovery in the world's most important economic regions. This recovery will be spearheaded by China and other emerging economies (2014 growth: 5.7%), followed by the USA (2014 growth: 3.0%). Europe, having fought against its sovereign debt crisis and financed several rescue packages for euro member states, will continue to lag behind (2014 growth: 1.1%).

Global demographic developments represent one of the most serious challenges facing the world. The dynamic growth in the world's population, together with an unprecedented increase in the elderly share of the population and the sharp rise in the number of people with access to medical care, represent key factors which will shape the 21st century. This situation is accompanied by scientific and technological progress, which is opening up ever new possibilities in the fields of medicine, research, diagnostics and life science.

These developments will lead not only to an increase in the numbers of clinical diagnostics tests to be performed, but will also result in new, unique business opportunities for which STRATEC is optimally positioned with its automation solutions and on which it will continue to focus its strategy and operations.

In view of the factors outlined above, global economic risks only have a very limited impact on STRATEC's business performance and business model. Moreover, long-term supply agreements with our customers minimize the potential implications of the crisis for STRATEC.

## REPORT ON FORECASTS AND OTHER STATEMENTS CONCERNING THE COMPANY'S EXPECTED DEVELOPMENT

Additional market launches and approvals of analyzer systems are expected in the current and coming years. Further development milestones have been reached to this end. Moreover, measures continue to be implemented to extend capacities within the company's existing structures.

One of the development and production projects started in 2012 was contractually finalized and signed in the first quarter of 2013. Further projects have reached promising stages of negotiation.

The volumes of in-vitro-diagnostics tests reported by leading global laboratory operators give reason to expect only a slow recovery in the market. The associated share of sales STRATEC generates with service parts is currently developing stably and has recovered slightly compared with 2012. Our customers' forecasts for analyzer systems continue not to be affected by government austerity or fiscal policy measures in the Euro or Dollar regions.

Our ability to issue precise forecasts continues to be limited by several external factors, such as capacity utilization rates at installed systems, the timing of further market launches, the planned production ramp-ups for new systems, further consolidation in the IVD market, and macroeconomic market factors. Based on the indicators and forecasts available to us, and given our current business performance, we expect to generate sales growth accompanied by increasing profitability in 2013. We plan to issue an update of the company forecast for the current financial year and subsequent years in the course of the first half of 2013.

Due to the immense debt accumulated by some countries and economic regions and the resultant potential implications (debt crisis), the level of budgeting reliability remains low for all industries, and for the global economy as a whole. This situation continues to harbor risks for STRATEC's customers and suppliers, as a result of which STRATEC also faces economic risks. The ongoing difficult economic climate also means that STRATEC continues to face increased market risk.

Apart from this, since the assessment of the company's situation provided on March 26, 2013 upon the compilation of the Annual Report for the 2012 financial year, no new information has arisen which could lead to any change in our assessment of the company's expected development.



## OPPORTUNITY AND RISK REPORT

We analyze and evaluate the risks facing the company and its business environment within the framework of our risk management system, which has been established as an early warning risk identification system. Furthermore, this system also includes a compliance system to ensure compliance with the relevant legal and industry-specific requirements.

STRATEC's business activities basically focus on sustainability and responsible behavior. In future, the company will document this in a sustainability report.

Apart from the factors outlined in the "Report on forecasts and other statements concerning the company's expected development", we do not see any changes compared with the risks and opportunities identified in the Group Management Report for the 2012 financial year dated March 26, 2013. Reference is made to the "Risk Report" section within the 2012 Group Management Report for details concerning our risk management system and our company's specific opportunity and risk profile.

# CONSOLIDATED BALANCE SHEET

as of March 31, 2013  
of STRATEC Biomedical AG

ASSETS in € thousands	03.31.2013	12.31.2012
<b>NON-CURRENT ASSETS</b>		
Goodwill	4,593	4,547
Other intangible assets	6,361	6,192
Property, plant and equipment	16,896	17,108
Interests in associates	289	363
Deferred tax assets	1,391	1,260
	<b>29,530</b>	<b>29,470</b>
<b>CURRENT ASSETS</b>		
Raw materials and supplies	10,091	8,857
Unfinished products, unfinished services	36,428	34,406
Finished products and goods	853	807
Trade receivables	21,555	23,802
Future receivables from construction contracts	6,070	6,627
Receivables from associates	57	96
Income tax receivables	2,687	2,016
Other receivables and other assets	2,134	2,182
Other financial assets	408	366
Cash and cash equivalents	18,680	13,209
	<b>98,963</b>	<b>92,368</b>
<b>TOTAL ASSETS</b>	<b>128,493</b>	<b>121,838</b>

SHAREHOLDERS' EQUITY AND DEBT in € thousands	03.31.2013	12.31.2012
<b>SHAREHOLDERS' EQUITY</b>		
Share capital	11,738	11,738
Capital reserve	16,296	16,247
Revenue reserves	63,025	48,966
Consolidated net income	3,544	13,973
Other equity	1,027	1,061
	<b>95,630</b>	<b>91,985</b>
<b>DEBT</b>		
<b>Non-current debt</b>		
Non-current financial liabilities	6,716	7,459
Pension provisions	28	28
Deferred taxes	2,052	2,060
	<b>8,796</b>	<b>9,547</b>
<b>Current debt</b>		
Current financial liabilities	1,707	1,183
Trade payables	5,544	4,288
Liabilities to associates	225	282
Other current liabilities	15,606	13,707
Current provisions	606	608
Income tax liabilities	379	238
	<b>24,067</b>	<b>20,306</b>
<b>TOTAL SHAREHOLDERS' EQUITY AND DEBT</b>	<b>128,493</b>	<b>121,838</b>

# CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

for the Period from January 1 to March 31, 2013  
of STRATEC Biomedical AG

in € thousands	01.01.-03.31.2013	01.01.-03.31.2012
<b>Sales</b>	<b>29,173</b>	<b>28,841</b>
Cost of sales	-19,110	-19,300
<b>Gross profit</b>	<b>10,063</b>	<b>9,541</b>
Research and development expenses	-944	-617
Information only: Total research and development expenses	-4,708	-4,836
Information only: Capitalized research and development expenses	3,764	4,219
Sales-related expenses	-2,184	-2,162
General administrative expenses	-2,382	-1,964
Other operating income	257	28
Other operating expenses	-404	-477
<b>EBIT</b>	<b>4,406</b>	<b>4,349</b>
Net financial expenses	-93	56
<b>Earnings before taxes (EBT)</b>	<b>4,313</b>	<b>4,405</b>
Current tax expenses	-894	-1,338
Deferred tax income	125	372
<b>Consolidated net income</b>	<b>3,544</b>	<b>3,439</b>
<b>Income and expenses recognized directly in equity (after taxes)</b>		
Currency translation of foreign financial statements	-34	50
<b>Comprehensive income</b>	<b>3,510</b>	<b>3,489</b>
<b>Earnings per share in €</b>		
No. of shares used as basis	11,725,522	11,662,672
<b>Earnings per share, diluted, in €</b>		
No. of shares used as basis, diluted	11,767,234	11,707,668

# CONSOLIDATED CASH FLOW STATEMENT

for the Period from January 1 to March 31, 2013  
of STRATEC Biomedical AG

in € thousands	01.01.-03.31.2013	01.01.-03.31.2012
Consolidated net income (after taxes)	3,544	3,439
Depreciation and amortization	898	975
Current income tax expenses	894	1,338
Income taxes paid less income taxes received	-1,422	-1,145
Financial income	-19	-63
Financial expenses	71	29
Interest paid	-24	-26
Interest received	35	59
Other non-cash expenses	103	29
Other non-cash income	-634	-503
<b>Cash flow</b>	<b>3,446</b>	<b>4,132</b>
Change in deferred taxes through profit or loss	-125	-372
Profit on disposals of non-current assets	0	-13
Increase in inventories, trade receivables and other assets	-536	-746
Increase in trade payables and other liabilities	3,026	3,179
<b>Inflow of funds from operating activities</b>	<b>5,811</b>	<b>6,180</b>
Incoming payments from disposals of non-current assets		
Property, plant and equipment	0	19
Outgoing payments for investments in non-current assets		
Intangible assets	-87	-94
Property, plant and equipment	-226	-645
Financial assets	0	-30
<b>Outflow of funds for investing activities</b>	<b>-313</b>	<b>-750</b>
Incoming payments from taking up of financial liabilities	0	76
Outgoing payments for repayment of financial liabilities	-196	-46
<b>Outflow (previous year: inflow) of funds for financing activities</b>	<b>-196</b>	<b>30</b>
<b>Cash-effective change in cash and cash equivalents</b>	<b>5,302</b>	<b>5,460</b>
<b>Cash and cash equivalents at start of period</b>	<b>13,209</b>	<b>19,548</b>
Change in scope of consolidation	84	0
Change in cash and cash equivalents due to changes in exchange rates	85	242
<b>Cash and cash equivalents at end of period</b>	<b>18,680</b>	<b>25,250</b>

# CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

for the Period from January 1 to March 31, 2013  
of STRATEC Biomedical AG

## JANUARY - MARCH 2012

in € thousands	Share capital	Capital reserve	Revenue reserves	
			Accumulated net income	Free revenue reserves
<b>Balance at 01.01.2012</b>	11,675	15,306	26,706	13,392
Allocations due to stock option plans		30		
Profit carried forward			15,282	
Comprehensive income				
<b>Balance at 03.31.2012</b>	11,675	15,336	41,988	13,392

## JANUARY - MARCH 2013

in € thousands	Share capital	Capital reserve	Revenue reserves	
			Accumulated net income	Free revenue reserves
<b>Balance at 01.01.2013</b>	11,738	16,247	32,574	16,392
Allocations due to stock option plans		45		
Profit carried forward			13,973	
Change in scope of consolidation		4		86
Comprehensive income				
<b>Balance at 03.31.2013</b>	11,783	16,296	46,547	16,478

	Consolidated net income	Other equity		Group equity
		Treasury stock	Currency translation	
	15,282	-212	1,082	83,231
				30
	-15,282			0
	3,439		50	3,489
	3,439	-212	1,132	86,750

	Consolidated net income	Other equity		Group equity
		Treasury stock	Currency translation	
	13,973	-212	1,273	91,985
				45
	-13,973			0
				90
	3,544		-34	3,510
	3,544	-212	1,239	95,630

# NOTES TO THE GROUP INTERIM REPORT

for the period from January 1 to March 31, 2013  
of STRATEC Biomedical AG

## Summary of principal accounting and valuation methods

The consolidated financial statements of STRATEC Biomedical AG as of December 31, 2012 were prepared in accordance with the International Financial Reporting Standards (IFRS) as adopted by the EU valid at the balance sheet date. In the interim report as of March 31, 2013, which has been prepared on the basis of International Accounting Standard (IAS) 34 "Interim Financial Reporting", application has been made of the same accounting methods as in the consolidated financial statements for the 2012 financial year. One exception relates to the first-time inclusion in the scope of consolidation of STRATEC Biomedical S.R.L., Romania, a company founded in the 2008 financial year. The implications of the first-time full consolidation of this company for the net asset, financial and earnings position of the STRATEC Group are of subordinate significance.

Application has also been made of all interpretations of the International Financial Reporting Interpretations Committee (IFRIC) with binding effect as of March 31, 2013.

There were no indications of any potential impairment in goodwill at the balance sheet date.

The company's interim reports are neither audited, nor subject to an audit review, by the group auditor, WirtschaftsTreuhand GmbH Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft, Stuttgart.

Reference is made to the consolidated financial statements of STRATEC Biomedical AG as of December 31, 2012 with regard to further information concerning the individual accounting and valuation methods applied.

The Group's currency is the euro. Unless otherwise indicated, all amounts have been stated in thousand euros (€ thousand).

## Segment disclosures

Apart from the first-time inclusion of STRATEC Biomedical S.R.L., Romania, in the "Instrumentation" segment, there have been no changes in segmentation compared with the consolidated financial statements as of December 31, 2012.

Segment data by operating segment for the period from January 1 to March 31, 2013

in € thousands	Instrumentation	All other segments	Reconciliation	Total
Sales	30,182	1,049	-2,058	29,173
EBIT	4,887	-227	-254	4,406
Assets	145,453	3,857	-20,817	128,493



Segment data by operating segment for the period from January 1 to March 31, 2012

in € thousands	Instrumentation	All other segments	Reconciliation	Total
Sales	29,943	836	-1,938	28,841
EBIT	5,123	-556	-218	4,349
Assets	133,203	3,555	-18,890	117,868

The breakdown of sales by geographical region represents the distribution of the STRATEC Group's products. As the customers of the STRATEC Group generally supply their country outlets and customers from their own central distribution centers, however, this breakdown of sales does not represent the geographical distribution of the final operating locations of the STRATEC Group's analyzer systems.

Sales can be broken down by geographical regions (customer locations) as follows:

in € thousands	Germany	EU	Other	Total
January - March 2013	6,155	12,047	10,971	29,173
	21.1%	41.3%	37.6%	100.0%

in € thousands	Germany	EU	Other	Total
January - March 2012	5,189	12,657	10,995	28,841
	18.0%	43.9%	38.1%	100.0%

### Research and development expenses

Research and development expenses not fulfilling the capitalization criteria set out in IAS 38 (Intangible Assets) amounted to € 0.9 million in the first three months of the 2013 financial year (previous year: € 0.6 million) and mainly involve personnel and material expenses. The STRATEC Group invested a total of € 4.7 million in research and development in the first three months of the 2013 financial year (previous year: € 4.8 million).

### Shareholders' equity

The development in shareholders' equity at the STRATEC Group has been presented in the consolidated statement of changes in equity on Pages 13 and 14.

The number of ordinary shares with a nominal value of € 1.00 each issued by STRATEC AG as of March 31, 2013, amounts to 11,737,745. These are all bearer shares.

### Disclosures on the volume of treasury stock and on subscription rights held by members of the company's executive and supervisory bodies and its employees pursuant to § 160 (1) Nos. 2 and 5 of the German Stock Corporation Act (AktG)

STRATEC AG owned a total of 12,223 treasury stock at the interim balance sheet date. This corresponds to a prorated amount of € 12,223.00 of the company's share capital and to a 0.10% share of its equity.

### Stock option programs

Members of the Board of Management / Managing Directors and employees held the following numbers of subscription rights (share option rights) at the interim balance sheet date:

	Board of Management / Managing Directors	Employees	Total
Outstanding on 01.01.2013	123,000	64,200	187,200
Issued	0	1,800	1,800
Exercised	0	0	0
Lapsed	0	0	0
Forfeited	0	0	0
Outstanding on 03.31.2013	123,000	66,000	189,000

A total of 1,800 stock option rights were granted to company employees on the basis of option agreements dated February 1, 2013.

### Employees

Including temporary employees the STRATEC Group had a total workforce of 541 employees as of March 31, 2013 (previous year: 512).

### Major events after the interim reporting date

No events of particular significance with material implications for the business performance of our Group have occurred since the interim balance sheet date.

### Responsibility statement

To the best of our knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim consolidated financial statements give a true and fair view of the assets, liabilities, financial position and profit or loss of the Group, and the interim management report of the Group includes a fair review of the development and performance of the business and the position of the Group, together with a description of the principal opportunities and risks associated with the expected development of the Group in the remainder of the financial year.

# ADDITIONAL INFORMATION

## FINANCIAL CALENDAR

<b>May 7, 2013</b>	Interim Report as of March 31, 2013
<b>June 6, 2013</b>	Annual General Meeting, Pforzheim, Germany
<b>July 23, 2013</b>	Interim Report as of June 30, 2013
<b>October 30, 2013</b>	Interim Report as of September 30, 2013
<b>November 2013</b>	German Equity Forum, Frankfurt/Main, Germany - Analysts' conference -

Furthermore, based on current planning, STRATEC will be taking part in the following capital market conferences in 2013:

<b>May 2013</b>	38th Annual dbAccess Health Care Conference, Boston, USA
<b>June 2013</b>	Jefferies 2013 Global Healthcare Conference, New York City, USA
<b>August 2013</b>	Commerzbank Sector Conference Week, Frankfurt / Main, Germany
<b>September 2013</b>	10 <sup>th</sup> Annual Goldman Sachs European Medtech and Healthcare Services Conference, London, UK Morgan Stanley Global Healthcare Conference, New York City, USA Goldman Sachs & Berenberg Bank German Corporate Conference, Munich, Germany

Partially incomplete / subject to amendment

## ABOUT STRATEC

STRATEC Biomedical AG designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies.

Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange.

Further information about STRATEC is available on the internet at [www.stratec.com](http://www.stratec.com).

## IMPRINT

### Published by

STRATEC Biomedical AG  
Gewerbestr. 37  
75217 Birkenfeld  
Germany

Phone: +49 7082 7916-0  
Fax: +49 7082 7916-999  
[info@stratec.com](mailto:info@stratec.com)  
[www.stratec.com](http://www.stratec.com)

### Investor Relations

ANDREAS KÜNZEL  
Phone: +49 7082 7916-185  
Fax: +49 7082 7916-999  
[a.kuenzel@stratec.com](mailto:a.kuenzel@stratec.com)

ANDRE LOY  
Phone: +49 7082 7916-190  
Fax: +49 7082 7916-999  
[a.loy@stratec.com](mailto:a.loy@stratec.com)

### NOTICE

Forward-looking statements involve risks: This interim report contains various statements concerning the future performance of STRATEC. These statements are based on both assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we can provide no guarantee of this. This is because our assumptions involve risks and uncertainties which could result in a substantial divergence between actual results and those expected. It is not planned to update these forward-looking statements.

This interim report contains various disclosures of an economic nature that do not form part of the relevant accounting requirements. These disclosures are to be viewed as a supplement to, rather than as a substitute for the disclosures made in accordance with IFRS.

Discrepancies may arise throughout this interim report on account of mathematical rounding up or down in the course of addition.

This interim report is also available in German.

**STRATEC BIOMEDICAL AG**

Gewerbestr. 37  
75217 Birkenfeld  
Germany

Phone: +49 7082 7916-0

Fax: +49 7082 7916-999

[info@stratec.com](mailto:info@stratec.com)

[www.stratec.com](http://www.stratec.com)